Postoophorectomy osteoporosis without current Mar 1, 2008 · However, it was noted that more women receiving anastrozole treatment became osteopenic, as compared with tamoxifen-treated women (anastrozole, n = 14; tamoxifen, n = 3)
As more women are exposed to AIs, it is important to understand their adverse effects on the skeleton
Treatment approaches to prevent aromatase inhibitor–induced bone loss typically consist of an antiresorptive approach with bisphosphonates or the RANKL
A 1-year analysis of the Arimidex®-Bondronat® study found that monthly ibandronate prevented bone loss in osteopenic women (n = 25) compared with placebo (n = 25) and in a small number of patients with preexisting
3 The
Five patients with osteopenia at baseline developed osteoporosis by five years, he said
osteoporosis or low bone mineral density
Osteoporosis is a skeletal disorder characterized by low bone mass and microarchitectural deterioration of the skeleton leading to bone fragility and a predisposition to fractures
Our bones start to thin after the age of 35 or so, as part of the natural ageing process
Common breast cancer treatments, such as aromatase inhibitors in postmenopausal women and chemotherapy-induced ovarian failure in premenopausal women, cause bone loss that in some women will lead to osteoporosis and fragility
Thirty-nine postmenopausal women treated with aromatase inhibitors for breast cancer were selected
The best-known form is the AIs-induced osteoporosis, whose molecular pathway and therapeutic possibilities were extensively investigated in the last decade
Aromatase converts androgens to estrogens in the ovaries and peripheral tissues such as adipose, liver, muscle, and breast
2012 May-Aug; 9(2): 89–91; Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al
The ARIBON trial is a double-blind, randomized, placebo-controlled study designed to
At 5 years, women taking anastrozole lost 6
You may be more likely to have a broken bone while using Arimidex
(See "Clinical features and evaluation of glucocorticoid-induced osteoporosis" and "Evaluation and management of aromatase inhibitor-induced bone loss" and "Bone disease with hyperthyroidism and thyroid hormone therapy"